PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of medicineHomeSearchSubmit a ManuscriptMedicine
 
Medicine (Baltimore). 2015 November; 94(45): e1173.
Published online 2015 November 13. doi:  10.1097/MD.0000000000001173
PMCID: PMC4912241

No Association of SERPINE1 −675 Polymorphism With Sepsis Susceptibility

A Meta-Analysis
Chengfang Shi, Dr, Zhifu Sui, Dr, Li Li, Dr, and Rongya Yang, PhD
Monitoring Editor: Undurti Das.

Abstract

The serine protease inhibitor clade E member 1 (SERPINE1) gene has been suggested to exert great influence on the development of sepsis. But there is little overlap in the results of association between SERPINE1 −675 4G/5G polymorphism and sepsis.

To get a more precise estimation of this association, we conducted a meta-analysis with a relatively larger sample size including 1806 cases and 2239 controls. Odds ratio (OR) with 95% confidence interval (CI) was used to evaluate the relationship between 675 4G/5G polymorphism and sepsis susceptibility. Subgroup analyses were conducted based on ethnicity and source of controls.

The results showed that there was no association of the SERPINE1 polymorphism and sepsis susceptibility (5G5G vs 4G4G: OR = 0.87, CI = 0.75–1.03; 5G5G+4G5G vs 4G4G: OR = 0.93, CI = 0.84–1.02; 5G5G vs 4G4G+4G5G: OR = 0.96, CI = 0.83–1.11; 5G vs 4G: OR = 0.94, CI = 0.86–1.01; 4G5G vs 4G4G: OR = 0.90, CI = 0.80–1.01). Nor did any subgroup analysis indicate a significant association.

In conclusion, −675 4G/5G polymorphism in the SERPINE1 gene may not be associated with the risk of sepsis.

INTRODUCTION

Sepsis is a kind of systemic inflammatory response syndrome (SIRS). It results from an immune response triggered by infections induced by bacteria, fungi, parasites, or viruses, with the primary infection more frequently seen in abdominal organs, brain, lungs, urinary tract, and skin.13 Common symptoms and signs of this whole-body inflammation include fever, polypnea, flushed skin, high heart rate, increased breathing rate, low blood pressure, or confusion.1 Despite the advance in effective antibiotics and supportive care, sepsis has a high mortality in critically ill patients.4 Identifying the predictive markers will help to better elucidate the disease pathogenesis. A series of genetic studies have investigated the role of serine protease inhibitor clade E member 1 (SERPINE1) in the pathogenesis of sepsis.5SERPINE1, also named plasminogen activator inhibitor-1 and PAI-1, is located on chromosome 7 (7q21.3-q22) in humans. It is a key member of serine proteinase inhibitor super family and serves as a main regulator of tissue and urinary plasminogen activators and fibrinolysis inhibitors.6,7 Results of previous research have established a linkage between the SERPINE1 gene and risk of sepsis.8 This finding was confirmed in recent reports, which also demonstrated high concentrations of SERPINE1 in patients sustaining meningococcal sepsis.9,10

There lies a single nucleotide insertion/deletion polymorphism (−675 4G/5G) in the promoter region. The recently described common promoter polymorphism is important in the transcription of SERPINE1 and the 4G allele has been correlated with higher plasma SERPINE1 activity.11 In addition, the 4G allele was reported to increase the risk of sepsis and related inflammation diseases such as pneumonia and trauma.1218

Among the published studies, there is little overlap in the results concerning the association between SERPINE1 −675 4G/5G and sepsis. Herein, meta-analysis was used to provide compelling evidence.

METHODS

Literature Search

We conducted a systematic computerized literature search of the PubMed, EMBASE, Science Direct, China national knowledge infrastructure (CNKI) and WanFang databases up to November 2014, to identify all articles that investigated the association of SERPINE1 −675 4G/5G polymorphism and sepsis, without language restrictions. Combinations of the following key words SERPINE1 or PAI-1, “polymorphism” or “variant” and “sepsis” were used. We also handsearched the references lists of all related review articles and the original articles considered eligible for the meta-analysis. In the meanwhile, the study was supported by the Research Ethics Committee of General Hospital of Beijing Military Region.

Inclusion and Exclusion Criteria

The studies were selected according to the following criteria: (a) evaluated the relationship between −675 4G/5G polymorphism and the risk of sepsis; (b) a case-control or cohort study; (c) provided sufficient data to calculate an odds ratio (OR) with 95% confidence interval (CI). Genetic association studies focusing on sepsis patients only or reporting limited data on genotype frequency were considered ineligible. Whenever several articles were overlapped in terms of subjects, only the largest article with complete genetic data was included in this meta-analysis.

Data Extraction

Data on name of first author, publication year, country, ethnicity, control source, genotyping method, numbers of cases and controls, genotype and allele frequencies in cases and controls and P value of Hardy–Weinberg equilibrium (HWE) were extracted by 2 investigators and subsequently checked by a 3rd investigator to assure data accuracy. The divergences, if any, were settled by discussion including a senior investigator.

Statistical Analysis

Fisher's test was adopted to test HWE in controls and P < 0.05 was considered significant disequilibrium. ORs with 95% CI were used to assess the relationship of SERPINE1 −675 4G/5G polymorphism with sepsis. Pooled ORs were calculated for 5G5G versus 4G4G, 5G5G+4G5G versus 4G4G, 5G5G versus 4G4G+4G5G, 5G versus 4G and 4G5G versus 4G4G, assuming homozygous, dominant, recessive, additive, and heterozygous genetic models, respectively. Both overall analyses and subgroup analyses based on ethnicity and source of controls were performed. The heterogeneity across the studies included in the meta-analysis was examined by the χ2-based Q-test, with the significance level defined at P < 0.05. In a case of significant heterogeneity, pooled ORs were calculated by the random-effects model; otherwise, the fixed-effects model was used. Potential publication bias was checked by Begg's funnel plot and further evaluated by Egger's weighted regression test. Sensitivity analysis was used to assess the stability of results. All statistical analyses were performed using Stata software (Version 12.0).

RESULTS

Characteristics of the Studies

As presented in Figure Figure1,1, 112 citations were identified through PubMed, EMBASE, and Science Direct databases and 27 additional citations were obtained from CNKI and WanFang. By scanning the title and abstract, we excluded 63 records with various reasons. We retrieved 76 full-text articles and examined their eligibility. Among these, 64 articles were excluded, because 14 focused on sepsis treatment, 3 used the same case series, 26 were designed as case-only studies, and 21 provided insufficient genotype data. Ultimately, 12 studies10,11,15,17,1926 with 1806 cases and 2239 controls were combined in the meta-analysis. As Table Table11 shows, 2 studies were conducted in Asian population and 10 in Caucasian samples. In addition, we included 4 hospital-based studies and 8 population-based studies.

FIGURE 1
Flow diagram of study selection in the meta-analysis.
TABLE 1
Characteristics of Eligible Studies in the Meta-analysis

Meta-Analysis

Using the fixed-effects homozygous model, we found individuals with the 5G5G genotype in comparison to individuals with 4G4G genotype had a decreased risk of sepsis, though the value did not reach the significance threshold (OR = 0.87, CI = 0.75–1.03) (Table (Table2).2). Likewise, other models tested did not indicate a significant association between SERPINE1 −675 4G/5G polymorphism and the risk for sepsis (5G5G+4G5G vs. 4G4G: OR = 0.93, CI = 0.84–1.02; 5G5G vs. 4G4G+4G5G: OR = 0.96, CI = 0.83–1.11; 5G vs. 4G: OR = 0.94, CI = 0.86–1.01; 4G5G vs. 4G4G: OR = 0.90, CI = 0.80–1.01) (Table (Table22).

TABLE 2
SERPINE1 −675 4G/5G Polymorphism and Sepsis Risk

We proceeded to subgroup analyses and no major effects were seen in any subgroup. Figures Figures22 and and33 illustrate the forest plots constructed for the homozygous model after stratification by ethnicity and source of controls, respectively.

FIGURE 2
Forest plot of association between SERPINE1 −675 4G/5G polymorphism and sepsis risk under the homozygous model by ethnicity.
FIGURE 3
Forest plot of association between SERPINE1 −675 4G/5G polymorphism and sepsis risk under the homozygous model by the control source.

Sensitivity Analysis and Publication Bias Test

Sensitivity analysis was carried out by deleting the single studies one by one to check their influence on the combined values. No substantial changes were seen in the pooled values. This suggested the stability of our meta-analysis results (data not shown). Symmetrical distribution was indicated in the funnel plots. More importantly, no evidence of high possibility of publication bias was found using Egger's weighted regression test (P = 0.105). Figure Figure44 shows the funnel plot constructed for the homozygous model.

FIGURE 4
Funnel plot constructed for the homozygous model.

DISCUSSION

SERPINE1 is considered to be a vital factor in the deregulation of fibrinolysis during the activity of coagulation in sepsis. It is suggested that increased plasma levels of SERPINE1 result in multiple organ dysfunction and subsequently increase the mortality of sepsis.2731 Plasma SERPINE1 concentrations are regulated by various factors. A functional polymorphism, −675 4G/5G, situated in the promoter region of the SERPINE1 gene has been described as an important regulator of plasma SERPINE1 levels. The presence of −675 4G/5G genotypes has been suggested to raise serum SERPINE1 concentrations, with the 4G/4G genotype associated with the highest levels, followed by the 5G/5G genotype, and the heterozygous genotype.32 It is this significant effect on serum concentrations of SERPINE1 that leads to much speculation of a causal association between the −675 4G/5G polymorphism and sepsis.

Recently, a number of studies representing various populations have been conducted to investigate the relationship between SERPINE1 −675 4G/5G polymorphism and the genetic risk of sepsis.10,15,17,19,20 The results, however, are controversial rather than conclusive. For example, a case-control study investigated multiple candidate genes among Turkish samples (42 sepsis cases and 113 controls), suggesting that the −675 4G/5G polymorphism is a susceptibility site for severe sepsis in children.21 The finding is consistent with a Caucasian study based on adult sepsis patients and an Asian study among children.12,25 In contrast, in a replication study by Zhan et al, the results suggested a significant association both at the genotypic and the allelic level among 89 cases and 100 controls of Han Chinese descent.22 More recently, Geishofer et al and Wingeyer et al lend further support for an increased risk of sepsis in relation to the presence of the 4G/4G genotype.20,23 The inconsistency either caused by heterogeneous populations or sampling variance requires a meta-analysis to compromise.

In our article, we demonstrated evidence that the presence of the −675 4G/5G polymorphism was not associated with genetic risk of sepsis. The present finding seems to contradict previous studies where the promoter polymorphism was shown to increase plasma SERPINE1 levels.32 However, it is likely that the −675 4G/5G polymorphism is a low-penetrance site and the minor effect can be detected in a larger analysis. It is also possible that the genetic predisposition to sepsis differs among individuals of different ancestries. Additional research with a larger sample and a variety of ethnic groups is clearly needed to investigate the aforementioned possibilities.

Several points should be concerned in interpreting the obtained results. First, previous research suggested significantly higher plasma SERPINE1 concentrations in patients with sepsis ascribed to the presence of the 4G allele or the 4G4G genotype.10 This implicates that the enhanced transcriptional activity induced by the mutation in the SERPINE1 promoter may represent a mechanism underlying the elevated levels of SERPINE1 in sepsis patients. But our meta-analysis did not show any evidence supporting an association. The most likely reason might relate to the limited sample size. Second, unadjusted ORs were used to estimate the genetic risk of sepsis. Common confounding factors such as the age and the gender were not considered. Third, we included some small studies. Therefore, publication bias may have been introduced, although the tests we utilized did not suggest such bias.

In conclusion, our meta-analysis results suggest that −675 4G/5G polymorphism in the promoter region of SERPINE1 gene may not contribute to the development of sepsis. Additional analyses are warranted in this chromosomal region to determine the association between the polymorphism site being investigated and incidence of sepsis in various ethnic populations.

Footnotes

Abbreviations: CI = confidence interval, CNKI = China national knowledge infrastructure, HWE = Hardy–Weinberg equilibrium, OR = odds ratio, SERPINE1 = serine protease inhibitor clade E member 1, SIRS = systemic inflammatory response syndrome.

CS and ZS equally contributed to this study.

The authors have no funding and conflicts of interest to disclose.

REFERENCES

1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250–1256. [PubMed]
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644–1655. [PubMed]
3. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63–78. [PubMed]
4. Dombrovskiy VY, Martin AA, Sunderram J, et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244–1250. [PubMed]
5. Esposito S, Zampiero A, Pugni L, et al. Genetic polymorphisms and sepsis in premature neonates. PloS one 2014; 9:e101248. [PMC free article] [PubMed]
6. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21:1104–1117. [PubMed]
7. Ulisse S, Baldini E, Sorrenti S, et al. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9:32–71. [PubMed]
8. Hermans PW, Hazelzet JA. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis 2005; 41 Suppl 7:S453–S458. [PubMed]
9. Herman R. Plasmodium chabaudi: host lymphocyte–macrophage interaction in vitro. Exp Parasitol 1977; 42:211–220. [PubMed]
10. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556–560. [PubMed]
11. Eriksson P, Kallin B, van ’t Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92:1851–1855. [PubMed]
12. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561–563. [PubMed]
13. Sapru A, Hansen H, Ajayi T, et al. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Anesthesiology 2009; 110:1086–1091. [PMC free article] [PubMed]
14. Yende S, Angus DC, Ding J, et al. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007; 176:1129–1137. [PMC free article] [PubMed]
15. Haralambous E, Hibberd ML, Hermans PW, et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003; 31:2788–2793. [PubMed]
16. Binder A, Endler G, Muller M, et al. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 2007; 5:2049–2054. [PubMed]
17. Garcia-Segarra G, Espinosa G, Tassies D, et al. Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007; 33:1354–1362. [PubMed]
18. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357:1096–1097. [PubMed]
19. Peres Wingeyer SD, Cunto ER, Nogueras CM, et al. Biomarkers in sepsis at time zero: intensive care unit scores, plasma measurements and polymorphisms in Argentina. J Infection Developing Countries 2012; 6:555–562. [PubMed]
20. Geishofer G, Binder A, Muller M, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005; 164:486–490. [PubMed]
21. Sipahi T, Pocan H, Akar N. Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis. Clin Appl Thromb/Hemost 2006; 12:47–54. [PubMed]
22. Zhan YZ, Wang HW, Chen DF, et al. Relationship between sepsis and 4G/5G polymorphism within the promoter region of plasminogen activator inhibitor-1 gene. Natl Med J China 2005; 85:2404–2407. [PubMed]
23. Wingeyer SP, de Larranaga G, Cunto E, et al. Role of 4G/5G promoter polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in outcome of sepsis. Thromb Res 2010; 125:367–369. [PubMed]
24. Li L, Nie W, Zhou H, et al. Association between plasminogen activator inhibitor-1-675 4G/5G polymorphism and sepsis: a meta-analysis. PloS One 2013; 8:e54883. [PMC free article] [PubMed]
25. Wei YD, Zeng QY, Zeng HS. 4G/5G promoter polymorphism in the plasminogen activator inhibitor 1 gene in children with sepsis. African Health Sci 2008; 3:280–285.
26. Henckaerts L, Nielsen KR, Steffensen R, et al. Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med 2009; 37:192–201.e191-193. [PubMed]
27. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765–3777. [PubMed]
28. Raaphorst J, Johan Groeneveld AB, Bossink AW, et al. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86:543–549. [PubMed]
29. Zeerleder S, Schroeder V, Hack CE, et al. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118:205–212. [PubMed]
30. Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001; 27:1853–1859. [PubMed]
31. Kornelisse RF, Hazelzet JA, Savelkoul HF, et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173:1148–1156. [PubMed]
32. Festa A, D’Agostino R, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107:2422–2427. [PubMed]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health